Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 295

1.

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.

Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL; GS-US-321-0102 Investigators.

Hepatology. 2018 Aug 28. doi: 10.1002/hep.30237. [Epub ahead of print]

PMID:
30153359
2.

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z.

J Hepatol. 2018 Aug 23. pii: S0168-8278(18)32295-5. doi: 10.1016/j.jhep.2018.08.013. [Epub ahead of print]

PMID:
30144554
3.

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease.

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA.

Gastroenterology. 2018 Jul 27. pii: S0016-5085(18)34815-7. doi: 10.1053/j.gastro.2018.07.027. [Epub ahead of print]

PMID:
30059671
4.

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ; GS-US-321-0105 and GS-US-321-0106 Investigators.

Gastroenterology. 2018 Jul 7. pii: S0016-5085(18)34758-9. doi: 10.1053/j.gastro.2018.07.006. [Epub ahead of print]

PMID:
29990488
5.

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.

Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, Ray AS, McHutchison JG, Subramanian GM, Myers RP, Middleton MS, Sirlin C, Loomba R, Nyangau E, Fitch M, Li K, Hellerstein M.

Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30404-X. doi: 10.1016/j.cgh.2018.04.042. [Epub ahead of print]

PMID:
29705265
6.

Correction: The effects of patient cost sharing on inpatient utilization, cost, and outcome.

Xu Y, Li N, Lu M, Dixon E, Myers RP, Jolley RJ, Quan H.

PLoS One. 2018 Apr 13;13(4):e0196039. doi: 10.1371/journal.pone.0196039. eCollection 2018.

7.

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de L├ędinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

Aliment Pharmacol Ther. 2018 Apr;47(7):989-1000. doi: 10.1111/apt.14529. Epub 2018 Feb 15.

PMID:
29446106
8.

Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.

Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, Subramanian M, McHutchison JG, Goodman Z.

Liver Int. 2018 Jan 27. doi: 10.1111/liv.13706. [Epub ahead of print]

PMID:
29377462
9.

DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.

Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM.

JCI Insight. 2018 Jan 25;3(2). pii: 96685. doi: 10.1172/jci.insight.96685. [Epub ahead of print]

10.

Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.

Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, Kowdley K, Muir AJ.

Hepatology. 2018 Jul;68(1):155-165. doi: 10.1002/hep.29664. Epub 2018 May 10.

PMID:
29152767
11.

The effects of patient cost sharing on inpatient utilization, cost, and outcome.

Xu Y, Li N, Lu M, Dixon E, Myers RP, Jolley RJ, Quan H.

PLoS One. 2017 Oct 26;12(10):e0187096. doi: 10.1371/journal.pone.0187096. eCollection 2017. Erratum in: PLoS One. 2018 Apr 13;13(4):e0196039.

12.

Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply.

Shaheen AA, Al-Mattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS.

Aliment Pharmacol Ther. 2017 Oct;46(8):770-771. doi: 10.1111/apt.14282. No abstract available.

PMID:
28901569
13.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators.

Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514. [Epub ahead of print] Erratum in: Hepatology. 2018 May;67(5):2063.

14.

Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.

Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS.

Aliment Pharmacol Ther. 2017 Sep;46(6):599-604. doi: 10.1111/apt.14218. Epub 2017 Jul 13.

PMID:
28707319
15.

Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.

Gharib AM, Han MAT, Meissner EG, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem KZ, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, Kottilil S, Heller T, Kovacs JA, Morse CG.

Biomed Res Int. 2017;2017:2067479. doi: 10.1155/2017/2067479. Epub 2017 Apr 5.

16.

On Foot Mat Use.

Myers RP.

J Am Coll Surg. 2017 May;224(5):1001. doi: 10.1016/j.jamcollsurg.2017.02.001. No abstract available.

PMID:
28449926
17.

Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

Fidai A, Dallaire F, Alvarez N, Balon Y, Clegg R, Connelly M, Dicke F, Fruitman D, Harder J, Myers K, Patton DJ, Prieur T, Vorhies E, Myers RP, Martin SR, Greenway SC.

Front Cardiovasc Med. 2017 Mar 27;4:15. doi: 10.3389/fcvm.2017.00015. eCollection 2017.

18.

Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.

Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K.

Clin Gastroenterol Hepatol. 2017 Jul;15(7):1087-1094.e2. doi: 10.1016/j.cgh.2017.01.032. Epub 2017 Feb 12.

PMID:
28215615
19.

Comparison of risk adjustment methods in patients with liver disease using electronic medical record data.

Xu Y, Li N, Lu M, Dixon E, Myers RP, Jolley RJ, Quan H.

BMC Gastroenterol. 2017 Jan 7;17(1):5. doi: 10.1186/s12876-016-0559-4.

20.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de L├ędinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.

PMID:
28039099

Supplemental Content

Loading ...
Support Center